Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Theranos Closes Labs, Focuses On New Medical Device

XTALKS VITALS NEWS

Elizabeth Holmes

As a result of the closures, Theranos will be laying-off 340 workers across California, Pennsylvania and Arizona.

Tweetables from this article:

Tweet: #Theranos will be laying-off 340 workers across California, Pennsylvania and Arizona http://ctt.ec/7u5lk+ Theranos will be laying-off 340 workers across California, Pennsylvania and Arizona.

Share this!

October 7, 2016 | by Sarah Hand, M.Sc.

In a surprising turn, Theranos founder Elizabeth Holmes has announced the company will be shutting down clinical testing labs and consumer blood testing services, in order to focus on its recently-unveiled miniLab medical device. As a result of the closures, Theranos will be laying-off 340 workers across California, Pennsylvania and Arizona.

Theranos’ novel blood testing technology has been the basis of the business since the beginning, but has recently faced controversy after the company voided thousands of test results in response to concerns over the technology’s accuracy. Amidst the controversy, Holmes received a 2 year ban from owning a blood testing laboratory from the Centers for Medicare & Medicaid Services (CMS).



“We will return our undivided attention to our miniLab platform,” said Holmes in an open letter on Theranos’ website. “Our ultimate goal is to commercialize miniaturized, automated laboratories capable of small-volume sample testing, with an emphasis on vulnerable patient populations, including oncology, pediatrics, and intensive care.”

The letter also refers to a new executive team at Theranos, an announcement that follows COO and President Sunny Balwani’s decision to resign earlier this year. Holmes also vows to pursue FDA approval for the new device, along with publications in peer-reviewed journals. The company has previously faced scrutiny over failing to publish data from their Edison medical device.

Their next focus – the miniLab medical device – was announced in August at the American Association for Clinical Chemistry (AACC) conference. Holmes claims the device will be able to use multiple diagnostic methods to analyze a small-volume blood sample using a single device.

“We’re pleased to share our technologies with the entire laboratory industry,” Holmes said of the miniLab device. “It’s the beginning of the next phase of the company, as we introduce our technologies to the world. We also will be working with academic institutions and other independent parties to validate and publish our results.”


Keywords: Blood Testing, Medical Device, Clinical Laboratory


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Canadian Regulator Recalls Pie Shells Over E. Coli Contaminated Flour

April 28, 2017 - Multiple brands of pie and tart shells are being recalled in Canada after the flour used to manufacture them was linked to 28 cases of illness due to infection with E. coli O121.

Featured In: Food News


FDA Sends Warning Letters to Manufacturers of Fake Cancer Drugs

April 27, 2017 - The FDA is cracking down on the sale of illegal cancer drugs by sending warning letters to 14 US companies selling the unapproved products.

Featured In: Life Science News, Drug Safety News


Womb-Like Device Could Increase Survival of Premature Babies

April 27, 2017 - Researchers at the Children's Hospital of Philadelphia (CHOP) have developed a womb-like device which mimics the environmental conditions found inside the uterus.

Featured In: Life Science News, Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Technology Solutions for Late Phase Research: Optimising Real World Data Assets


Serialization for Late Starters – With Live Industry Research Results


Clinical Not All Antioxidants Are Created Equal: Astaxanthin, The Antioxidant Powerhouse


The New Gold Standards of IRT Delivery for Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.